The prevalence of antibiotic resistance among gram negative bacilli from intensive care units in Oman

Saudi Medical Journal

Volumn 20, Issue 5, 1999, Pages 373-377

  Elhag, Kamal M ^a   Reed, Martina ^a   Al Lawaty, Hassan M ^a  

^a ROYAL HOSPITAL   (Oman)

Author keywords

lactamase; Gram negative bacteria; Intensive care units; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; FUSIDIC ACID; GENTAMICIN; IMIPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDUCATION PROGRAM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MEDICAL AUDIT; OMAN; PSEUDOMONAS AERUGINOSA;

EID: 0032887043     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antimicrobial agent use. Rev Infect Dis 1983; 5: 1033-1048.
2. Jacobson KL, Cohen SH, Inciardi JF. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group 1 beta-lactamase producing organisms. Clin Infect Dis 1995; 21: 1107-1113.
3. Knothe H, Shah P, Kremery V, Anatal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-317.
4. Jacoby FA, Medeiros AA. More extended-spectrum β-lactamases. Amtimicob Agents Chemother 1991; 35: 1697-1704.
5. Livermore DM, Yuan M. Antimicrobial agent resistance and production of extended-spectrum β-lactamases among Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-424.
6. Young LS, Hindler J. Aminoglycoside resistance: a world wide prospective. Am J Med 1986; (Suppl 6b): 15-21.
7. Casellas JM, Blanco MG, Pinto ME. The sleeping giant. Antimicrobial resistance. Infect Dis Clin N Amer 1994; 8: 29-45.
8. Elhag KM, Al-Lawaty HM, Sultan B. All about Royal Hospital Bugs. Oman Medical Journal 1996; 13: 40-46.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests, 5th ed. (M2-A5). National Committee for Clinical Laboratory Standards, Villanova, Pa, 1993.
10. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353-358.
11. Rello R, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator associated pneumonia. Chest 1993; 104: 1230-1235.
12. Chow J, Fine M, Shlaes D et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
13. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP et al. Differences in the resistant variants of Enterobacter cloacae selected by extended spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 1289-1293.
14. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiolo Rev 1995; 8: 557-584.
15. Spencer RC, Bauernfeind A, Garciar-Rodriguez J, Jarlier V, Pfaller M, Turnidge J, Voss A. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin Microbiol Infect 1997; 3(suppl 1): S21-35.
16. Livermore DM, Yuan M. Antimicrobial agent resistance and production of extended-spectrum β-lactamases among Klebsiella spp. from intensive care units in Europe. J Antimicob Chemother 1996; 38: 409-424.
17. Castellas JM, Blanco MG, Pinto ME. The sleeping giant. Antibiotic resistance. Infect Dis Clin N Amer 1994; 8: 29-45.
18. Bergogne-Berezin E, Towner KJ. Acinetobacter as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996; 9: 148-165.
19. Payne DJ. Metallo-β-lactamases - A new therapeutic challenge. J Med Microbiol 1993; 39: 93-99.
20. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30(suppl): S453-464.
21. Burwen DR, Banjere SN, Gaynes RP, the National Infections Surveillance System. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis 1994; 170: 1622-1625.
22. Stapleton P, Shannon K, Phillips I. The ability of β-lactam antimicrobials to select mutants with derepressed β-lactamase synthesis from Citrobacter freundii. J Antimicrob Chemother 1995; 36: 483-496.
23. Vura-Papp U, Kayser FH, Hadorn K, Weiderkehr F. Mechanism of imipenem resistance acquired by 3 Pseudomonas aeruginosa strains during imipenem therapy. Eur J Clin Microbiol Infect Dis 1990; 9: 580-587.
24. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D et al. Effect of sulbactam on infections caused by imipenemresistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167: 448-451.
25. Radberg G, Nilsson LE, Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother 1990; 34: 2142-2147.